Brentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, nearly-stage classical Hodgkin lymphoma
The study demonstrates high efficacy and acceptable safety of the combination of brentuximab vedotin and nivolumab with doxorubicin and dacarbazine (AN+AD) in patients with early‑stage classical Hodgkin lymphoma.
Part of the source_content was not a traditional abstract, therefore the abstract field is omitted.
The trial indicates that adding novel immunotherapies to abbreviated chemotherapy can achieve near‑complete cure rates while potentially reducing treatment intensity and long‑term toxicity in early‑stage classical Hodgkin lymphoma.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Advanced Classical Hodgkin Lymphoma Management in East and Southeast Asia: Real-World Challenges and Aspirations of the Asian Lymphoma Study Group.
- Overcoming PD‑1 Resistance in Relapsed/Refractory Hodgkin Lymphoma
- Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era
- Late cardiopulmonary morbidity in patients with Hodgkin lymphoma: a retrospective nationwide registry study
- Combination of Acimtamig and AlloNK Effective in R/R Classical Hodgkin Lymphoma